Lates News

AstraZeneca: Baxidulten achieved the primary endpoint and all secondary endpoints in the BaxHTN Phase III trial. The 2mg dose of Baxidulten reduced systolic blood pressure by 15.7 mmHg compared to baseline levels. Baxidulten was generally well tolerated, and no unexpected safety issues were identified.